DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
LY2606368 is an investigational drug.
There have been 16 clinical trials for LY2606368. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2014.
The most common disease conditions in clinical trials are Neoplasms, Preleukemia, and Ovarian Neoplasms. The leading clinical trial sponsors are Eli Lilly and Company, Dana-Farber Cancer Institute, and Children's Oncology Group.
There are three US patents protecting this investigational drug and sixty-four international patents.
Recent Clinical Trials for LY2606368
|Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors||Eli Lilly and Company||Phase 1|
|Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors||St. Jude Children's Research Hospital||Phase 1|
|Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial||Eli Lilly and Company||Phase 1|
Top disease conditions for LY2606368
Top clinical trial sponsors for LY2606368
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|LY2606368||Start Trial||5-(5-(2-(3-aminopropdoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2- -carbonitfile (S)-lactate monohydrate||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|LY2606368||Start Trial||Targeted therapeutics||MADRIGAL PHARMACEUTICALS, INC. (West Conshohocken, PA)||Start Trial|
|LY2606368||Start Trial||5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-- carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts||Eli Lilly and Company (Indianapolis, IN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|